Search
Artelo Biosciences Inc
ARTLAdd to Watchlist
1.110USD
+0.010+0.91%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
747.04KMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
+0.91%
5 Days
-0.89%
1 Month
-22.38%
6 Months
-70.87%
Year to Date
-69.67%
1 Year
-88.96%
Key Figures
1.110Open
1.110High
135.69KVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
20.16%Turnover Ratio
1.100Prev. Close
1.060Low
95.33KTurnover
LossP/E Static
0.11P/B
0.00%Div Yield TTM
-167.97%ROA
85.80052wk High
0.57Volume Ratio
-9.83MNet Profit
673.01KShares
-28.5377EPS TTM
-0.09Beta
-367.70%ROE
1.19052wk Low
4.55%Amplitude
--Gross Margin
747.04KMarket Cap
-2.85Reward/Risk
8.10%Risk Rate
TradingKey Stock Score of Artelo Biosciences Inc
Currency: USD Updated: 2026-07-02Key Insights
Artelo Biosciences Inc's fundamentals are relatively healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 180 out of 387 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Hold, with the highest price target at 30.00.In the medium term, the stock price is expected to trend down.Despite a very weak market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Artelo Biosciences Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Artelo Biosciences Inc Highlights
StrengthsRisks
Artelo Biosciences, Inc. is a clinical-stage pharmaceutical company dedicated to the development and commercialization of therapeutics that modulate lipid-signaling pathways. The Company is advancing a portfolio of broadly applicable product candidates designed to address significant unmet needs in multiple diseases and conditions, including anorexia, cancer, anxiety, dermatologic conditions, pain, and inflammation. Its pipeline products include ART26.12, ART27.13 and ART12.11. ART26.12, its Fatty Acid Binding Protein 5 (FABP5) inhibitor, is being developed as a novel, peripherally acting, non-opioid, non-steroidal analgesic. The Cancer Appetite Recovery Study (CAReS) is a Phase 1/2 randomized, placebo-controlled trial of its clinical program, ART27.13, in patients with cancer anorexia and weight loss. ART12.11, the Company's novel solid-state cannabidiol composition co-formed with tetramethylpyrazine, is targeted for development in anxiety disorders and rare/orphan diseases.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 0.00.
Overvalued
The company’s latest PE is -0.04, at a high 3-year percentile range.
Institutional Buying
The latest institutional holdings are 34.88K shares, increasing 22.85% quarter-over-quarter.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of -0.63.
Analyst Rating
Based on
1
analysts
Hold
Current Rating
30.000
Target Price
+471.43%
Upside Space
Artelo Biosciences Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Artelo Biosciences Inc Info
Artelo Biosciences, Inc. is a clinical-stage pharmaceutical company dedicated to the development and commercialization of therapeutics that modulate lipid-signaling pathways. The Company is advancing a portfolio of broadly applicable product candidates designed to address significant unmet needs in multiple diseases and conditions, including anorexia, cancer, anxiety, dermatologic conditions, pain, and inflammation. Its pipeline products include ART26.12, ART27.13 and ART12.11. ART26.12, its Fatty Acid Binding Protein 5 (FABP5) inhibitor, is being developed as a novel, peripherally acting, non-opioid, non-steroidal analgesic. The Cancer Appetite Recovery Study (CAReS) is a Phase 1/2 randomized, placebo-controlled trial of its clinical program, ART27.13, in patients with cancer anorexia and weight loss. ART12.11, the Company's novel solid-state cannabidiol composition co-formed with tetramethylpyrazine, is targeted for development in anxiety disorders and rare/orphan diseases.
Ticker SymbolARTL
CompanyArtelo Biosciences Inc
CEOGorgas (Gregory D)
Websitehttps://artelobio.com/
Related Instruments
+1.62%
+3.50%
+6.14%
+3.96%
+3.31%
+3.72%
+3.55%
+3.40%
+4.21%
+1.80%
+6.03%
+4.11%
+4.62%
+3.68%
+2.35%
0.00%
+4.73%
+3.32%
+0.41%
+4.98%Popular Instruments
52852.900
+10.400 (+0.02%)
29669.900
+358.500 (+1.22%)
7507.800
+36.300 (+0.49%)
14963.000
+160.000 (+1.08%)
69676.000
+1528.000 (+2.24%)
6412.400
+59.600 (+0.94%)
68.683
+0.339 (+0.50%)
308.630
+14.250 (+4.84%)
194.830
-2.750 (-1.39%)
4174.610
+52.700 (+1.28%)
FAQs
What is the current price of Artelo Biosciences Inc (ARTL)?
The current price of Artelo Biosciences Inc (ARTL) is 1.11.
What is the symbol of Artelo Biosciences Inc?
The ticker symbol of Artelo Biosciences Inc is ARTL.
What is the 52-week high of Artelo Biosciences Inc?
The 52-week high of Artelo Biosciences Inc is 85.80.
What is the 52-week low of Artelo Biosciences Inc?
The 52-week low of Artelo Biosciences Inc is 1.19.
What is the market capitalization of Artelo Biosciences Inc?
The market capitalization of Artelo Biosciences Inc is 747.04K.
Is Artelo Biosciences Inc (ARTL) currently rated as Buy, Hold, or Sell?
According to analysts, Artelo Biosciences Inc (ARTL) has an overall rating of signal_hold, with a price target of 30.00.
What is the Earnings Per Share (EPS TTM) of Artelo Biosciences Inc (ARTL)?
The Earnings Per Share (EPS TTM) of Artelo Biosciences Inc (ARTL) is -37.55.